Cargando…

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3

BACKGROUND: Epidermal growth factor receptor (EGFR) is suggested to predict the radiosensitivity and/or prognosis of human esophageal squamous cell carcinoma (ESCC). The objective of this study was to investigate the efficacy of Nimotuzumab (an anti-EGFR monoclonal antibody) on ESCC radiotherapy (RT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lei, He, Li-Ru, Xi, Mian, Cai, Mu-Yan, Shen, Jing-Xian, Li, Qiao-Qiao, Liao, Yi-Ji, Qian, Dong, Feng, Zi-Zhen, Zeng, Yi-Xin, Xie, Dan, Liu, Meng-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540017/ https://www.ncbi.nlm.nih.gov/pubmed/23232108 http://dx.doi.org/10.1186/1479-5876-10-249

Ejemplares similares

Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line
por: Li, Jiancheng, et al.
Publicado: (2019)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
por: Huang, Jianfeng, et al.
Publicado: (2018)

Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2015)

Upregulation of microRNA-98 increases radiosensitivity in esophageal squamous cell carcinoma
por: Jin, Ying-Ying, et al.
Publicado: (2016)

Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair
por: Qu, Yuan-yuan, et al.
Publicado: (2013)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Overexpression of IGFBP5 Enhances Radiosensitivity Through PI3K-AKT Pathway in Prostate Cancer
por: Chen, Xue, et al.
Publicado: (2020)

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
por: Diaz-Miqueli, Arlhee, et al.
Publicado: (2013)

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells
por: YANG, XIAOYU, et al.
Publicado: (2016)

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair
por: Liu, Hai, et al.
Publicado: (2015)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Enhanced Expression of IGFBP-3 Reduces Radiosensitivity and Is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma
por: Sakata, Junki, et al.
Publicado: (2020)

The Modified Glasgow Prognostic Score Is an Independent Prognostic Factor in Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy
por: Zhang, Peng, et al.
Publicado: (2014)

Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
por: Bernhard, Wendy, et al.
Publicado: (2023)

ETV5 overexpression promotes progression of esophageal squamous cell carcinoma by upregulating SKA1 and TRPV2
por: Sun, Ming-Chuang, et al.
Publicado: (2022)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
por: Sun, Dantong, et al.
Publicado: (2020)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

The Diagnostic Value of Serum IGFBP7 in Patients with Esophageal Squamous Cell Carcinoma
por: Huang, Xinyi, et al.
Publicado: (2019)

Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2015)

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma
por: An, Lingbo, et al.
Publicado: (2023)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

Down-regulation of XIAP enhances the radiosensitivity of esophageal cancer cells in vivo and in vitro
por: Wen, Xin, et al.
Publicado: (2017)

Effect of sinomenine hydrochloride on radiosensitivity of esophageal squamous cell carcinoma cells
por: Fu, Shenbo, et al.
Publicado: (2018)

LAPTM4B knockdown increases the radiosensitivity of EGFR-overexpressing radioresistant nasopharyngeal cancer cells by inhibiting autophagy
por: Chu, Chu, et al.
Publicado: (2019)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
por: Liang, Jun, et al.
Publicado: (2013)

Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone
por: Zhang, Peng, et al.
Publicado: (2014)

IL-32 Promotes the Radiosensitivity of Esophageal Squamous Cell Carcinoma Cell through STAT3 Pathway
por: Ma, Zhiyu, et al.
Publicado: (2021)

Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
por: Bernhard, Wendy, et al.
Publicado: (2017)

Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
por: Hartimath, Siddesh V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0diaima56k9jmcq6timvpka5gi